iRhythm Holdings, Inc. is a digital healthcare company, which engages in the provision of design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services. The company is headquartered in San Francisco, California and currently employs 2,400 full-time employees. The company went IPO on 2016-10-20. The firm's principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. The firm provides Zio ambulatory cardiac monitoring services, including long-term continuous monitoring (LTCM), short-term continuous monitoring, and mobile cardiac telemetry (MCT) monitoring services, using a proprietary system that combines an FDA-cleared and CE-marked wire-free, patch-based, 14-day wearable biosensor that continuously records ECG data, with a proprietary FDA-cleared, CE-marked, Japan PDMA approved cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
Forward revenue growth (NTM) 
